Millipore Sigma Vibrant Logo

215902 Carbonic Anhydrase IX Inhibitor III, Methazolamide - CAS 554-57-4 - Calbiochem

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide, Carbonic Anhydrase Inhibitor, Methazolamide, CAIX Inhibitor III

Primary Target: carbonic anhydrase
215902
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
—
Solicitar precio
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      CAS #Empirical Formula
      554-57-4C₅H₈N₄O₃S₂
      Description
      Overview

      This product has been discontinued.



      A cell-permeable thiadiazolylsulfonamide derivative that acts as a carbonic anhydrase (CA) inhibitor (Ki = 20 nM) with anti-glaucoma, anti-diabetic, and potential anti-neoplastic activity. May induce death in hypoxic tumor cells by inhibiting tumor-associated CAIX in maintaining an acidic tumor microenvironment, and blocking CAIX-dependent resistance to chemotherapy in these tumors. Shown to enhance insulin sensitivity and reduce HbA1c levels in diabetic rodent models in a dose-dependent manner. Shown to reduce oxygen and glucose-deprived cell death in primary cerebrocortical neurons by diminishing the release of cytochrome c and dissipating the mitochondrial membrane potential gradient.
      Catalogue Number215902
      Brand Family Calbiochem®
      SynonymsN-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide, Carbonic Anhydrase Inhibitor, Methazolamide, CAIX Inhibitor III
      References
      ReferencesMaren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
      Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
      Wang, X., et al. 2009. Stroke. 40, 1877.
      Konstantopoulos, N., et al. 2012. Diabetes.
      Product Information
      CAS number554-57-4
      FormWhite powder
      Hill FormulaC₅H₈N₄O₃S₂
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetcarbonic anhydrase
      Primary Target K<sub>i</sub>20 nM
      Purity≥99% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      215902 0

      Documentation

      Carbonic Anhydrase IX Inhibitor III, Methazolamide - CAS 554-57-4 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Carbonic Anhydrase IX Inhibitor III, Methazolamide - CAS 554-57-4 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      215902

      Referencias bibliográficas

      Visión general referencias
      Maren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
      Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
      Wang, X., et al. 2009. Stroke. 40, 1877.
      Konstantopoulos, N., et al. 2012. Diabetes.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision30-October-2012 JSW
      SynonymsN-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide, Carbonic Anhydrase Inhibitor, Methazolamide, CAIX Inhibitor III
      DescriptionA cell-permeable thiadiazolylsulfonamide derivative that acts as a carbonic anhydrase (CA) inhibitor (Ki = 20 nM) with anti-glaucoma, anti-diabetic, and potential anti-neoplastic activity. May induce death in hypoxic tumor cells by inhibiting tumor-associated CAIX in maintaining an acidic tumor microenvironment, and blocking CAIX-dependent resistance to chemotherapy in these tumors. Shown to enhance insulin sensitivity and reduce HbA1c levels in diabetic rodent models in a dose-dependent manner. Shown to reduce oxygen and glucose-deprived cell death in primary cerebrocortical neurons by diminishing the release of cytochrome c and dissipating the mitochondrial membrane potential gradient.
      FormWhite powder
      Intert gas (Yes/No) Packaged under inert gas
      CAS number554-57-4
      Structure formulaStructure formula
      Purity≥99% by HPLC
      SolubilityDMSO (50 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesMaren, T., et al. 1977. Invest Ophthalmol Vis Sci. 16, 730.
      Chegwidden, W. R. and Spencer, I. M. 1995. Inflammopharmacology. 3, 231.
      Wang, X., et al. 2009. Stroke. 40, 1877.
      Konstantopoulos, N., et al. 2012. Diabetes.